16.52
전일 마감가:
$22.68
열려 있는:
$15.47
하루 거래량:
7.45M
Relative Volume:
6.62
시가총액:
$1.40B
수익:
$42.95M
순이익/손실:
$-130.01M
주가수익비율:
-10.15
EPS:
-1.6278
순현금흐름:
$-19.66M
1주 성능:
-27.48%
1개월 성능:
-31.74%
6개월 성능:
-19.49%
1년 성능:
+233.74%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics Inc
|
16.52 | 1.91B | 42.95M | -130.01M | -19.66M | -1.6278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Income Statement - TradingKey
Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE - TradingView
Monte Rosa Therapeutics Inc (GLUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.570|Chg%:-0.210 - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.780|Chg%:-0.250 - TradingKey
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics Market Sentiment - Benzinga España
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Nearly 9,500 Shares at $23.18 Average Price - Kalkine Media
Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each - Stock Titan
Form 144 MONTE ROSA THERAPEUTICS For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock - Investing.com UK
Price to book forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock By Investing.com - Investing.com Nigeria
Form 4 Monte Rosa Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics COO Jennifer Champoux Completes Stock Sales, Option Exercise, and New Grant Under Pre-Arranged Rule 10b5-1 Plan - Kalkine Media
Monte Rosa Therapeutics (GLUE) COO trades 4,351 shares via option exercise - Stock Titan
GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144 - Stock Titan
Enterprise value to EBIT forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position - MarketBeat
Monte Rosa COO Jennifer Champoux disposes of 4,351 common shares worth $101,707.28 - Bitget
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise - Stock Titan
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com - Investing.com India
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 13D/A Monte Rosa Therapeutics For: 6 July By Investing.com - Investing.com South Africa
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monte Rosa Therapeutics Inc 주식 (GLUE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
자본화:
|
볼륨(24시간):